Literature DB >> 2569102

Hepatitis C virus antibodies among risk groups in Spain.

J I Esteban1, R Esteban, L Viladomiu, J C López-Talavera, A González, J M Hernández, M Roget, V Vargas, J Genescà, M Buti.   

Abstract

The frequency of hepatitis C virus (HCV) infection in Spain was assessed by means of a recombinant-based immunoassay for serum anti-HCV antibodies. 836 serum samples were tested from 676 patients selected according to their risk of blood-borne viral infections and presence of liver disease. Among patients at high risk of infection (with or without liver disease) anti-HCV antibodies were found in 85% of prospectively followed patients with post-transfusion non-A, non-B hepatitis, 62% of patients with chronic hepatitis or cirrhosis and a history of blood transfusion, 70% of haemophiliacs receiving replacement therapy, 70% of intravenous drug abusers, and 20% of haemodialysis patients. Only 8% of homosexual men infected with human immunodeficiency virus and 6% of female contacts of drug abusers were positive. Among patients with liver disease and no history of parenteral exposure to blood, anti-HCV antibodies were detected in 38% with cryptogenic, alcoholic, or primary biliary cirrhosis and in 44% with chronic active hepatitis. Among healthy subjects without risk factors for hepatitis the overall prevalence of anti-HCV was 1.2%.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2569102     DOI: 10.1016/s0140-6736(89)90485-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  150 in total

1.  Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology.

Authors:  J Devlin; J O'Grady
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

2.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

3.  Hepatitis C virus infection in cocaine users--a silent epidemic.

Authors:  H H Harsch; J Pankiewicz; A S Bloom; C Rainey; J K Cho; L Sperry; E A Stein
Journal:  Community Ment Health J       Date:  2000-06

Review 4.  Hepatic manifestations of autoimmune rheumatic diseases.

Authors:  S Abraham; S Begum; D Isenberg
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

5.  Detection of hepatitis C virus-specific antigens in semen from non-A, non-B hepatitis patients.

Authors:  G J Kotwal; V K Rustgi; B M Baroudy
Journal:  Dig Dis Sci       Date:  1992-05       Impact factor: 3.199

6.  Prevalence of antibodies to hepatitis C virus in Italian health care workers.

Authors:  M Libanore; R Bicocchi; F Ghinelli; G Palumbo; M Moretti; P Pazzi; L Scalambra
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

7.  Hepatitis C virus antibodies in homosexual men and intravenous drug users in Denmark.

Authors:  H Westh; A M Worm; B L Jensen; S Kroon; B Kvinesdal; C M Nielsen; P Wantzin
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

8.  Lower prevalence of anti-hepatitis C antibody in dialysis and renal transplant patients in Ireland.

Authors:  P J Conlon; J J Walshe; E G Smyth; E B McNamara; J Donohoe; M Carmody
Journal:  Ir J Med Sci       Date:  1993-04       Impact factor: 1.568

9.  Hepatitis C markers in hemodialysis patients.

Authors:  C S Huang; M S Ho; C S Yang; C L Lee; C A Tan
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

10.  Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3.

Authors:  P Simmonds; K A Rose; S Graham; S W Chan; F McOmish; B C Dow; E A Follett; P L Yap; H Marsden
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.